From 1999 to 2002, Dr. Tarwater was an assistant research professor at the Bloomberg School of Public Health. Dr. Tarwater's research included bivariate processes and nonlinear models for characterization of trajectories of immunologic markers after treatment in HIV-studies, the comparison of methods to determine the effectiveness of antiretroviral therapies at the population level in HIV-1 incident and prevalent cohorts, the impact of antiretroviral therapy on the trajectories of immunologic and virologic markers of disease progression, and longitudinal assesments of HIV prgrerssion markers among those who discontinued HARRT. Dr. Tarwater collaborated closely with investigators of the Multicenter AIDS Cohort Study (MACS) and the Women's Interagency HIV Study (WIHS). Current collaborations with the Retrovirus Labortatory within the Department of Comparative Medicine at the Hopkins School of Medicine have focused on research identifying the neuropathy of HIV disease and treatments via SIV macaque model of HIV progression.

Biostatistics, Epidemiology, Survival Analysis, Longitudinal Data Analysis, HIV/AIDS

Detels R, Tarwater PM, Phair JP, Margolick J, Riddler SA, and Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15:347-355.

Tarwater PM, Margolick J, Jin J, Phair J, Detels R, Rinaldo C, Giorgi J, and Muñoz A. Increase and plateau of CD4 T cell counts in the 3 ½ years following initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:168-75

Sacktor N, Tarwater PM, Skolasky MA, McArthur JC, Selnes A, Becker J, Cohen B, Miller EN. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology 2001; 57:542-5.

Tarwater PM, Mellors J, Gore ME, Margolick J, Phair J, Detels R, and Muñoz A Methods to assess population effectiveness of therapies in HIV incident and prevalent cohorts. Am J Epidemiol 2001; 154:675-81.

Babas T, Vieler E, Hauer DA, Adams RJ, Tarwater PM, Fox KJ, Clements JE, and Zink MC. Pathogenesis of SIV pneumonia: selective replication of viral genotypes in the lung. Virology 2001; 2:371-81.

Zink MC, Coleman GD, Mankowski JL, Adams RJ, Tarwater PM, Fox KJ, Clements JE. Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts the development of simian immunodeficiency virus encephalitis. J Inf Dis 2001; 184:1015-21.

Augenbraun M, Tarwater PM., Greenblatt R, Cohen M, Gore ME, Watts H, Preston-Martin S, and Anastos K. Opportunistic infection (OI) prophylaxis in the Women’s Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 2001;28:195-6.

Tarwater PM, and Martin CF. Effects of population density on the spread of disease. Complexity 2001; 6(6):29-36.

Mankowski JL, Queen SE, Tarwater PM. Fox KJ, Perry VH, Clements JE. Axonal ?-Amyloid Precursor Protein Accumulation in SIV-infected Macaques. J Neuropathol Exp Neurol 2002; 61(1):85-90.

Clements JE, Babas T, Mankowski J, Suryanarayana K, Piatak MJ, Tarwater PM, Lifson JD, and Zink MC. CNS as a reservoir for SIV: stable levels of SIV DNA in the brain from acute through asymptomatic infection. J Infect Dis 2002; 186(7):905-13.

Babas T, Muñoz D, Mankowski J, Tarwater PM, Clements JE, and Zink MC. Pathogenesis of SIV pneumonia: selective replication of SIV genotypes in brain and microglial cells. J Virol 2003; 77(1):208-216.

Mankowski JL, Queen SE, Tarwater PM, Adams RJ, and Guilarte TR. Elevated peripheral benzodiazpine receptor expression in SIV encephalitis. J Neurovirology 2003; 9(1):94-100.

Philpott S, Weiser B, Tarwater PM, Kleeberger C, Vermund S, Gange S, Anastos K, Cohen M, Greenblatt R, Kovacs A, Minkoff H, Young M, Miotti P, Dupuis M, Chen CH, Burger H. The association of CCR5 geneotype with HIV-1 infection, disease progression and response to potent therapy in Women. J Infect Dis 2003; 187(4):569-575.

Li X, Buechner JM, Tarwater PM, Muñoz A. An Equiponderant Graphical Display of the Effects of Two Categorical Predictors on Continuous Outcomes. Am Statistician 2003; 57(3):193-199.

Marx MA, Murugavel KG, Tarwater PM, SriKrishman AK, Thomas DL, Solomon S, and Celentano DD. Examination of the association between HCV and genital ulcers in a multi-level random sample of slum residents in southern India. Clin Infect Dis 2003; 37:514-520.

Sacktor N, Skolasky RL, Tarwater, PM, McArthur JC, Selnes OA, Becker J, Cohen B, and Miller EN. Systemic HIV viral load suppression and rebound correlate with psychomotor speed performance. Neurology 2003; 61(4):567-9.

Tarwater PM, Parrish MA, and Gallant JE. Prolonged treatment interruption after immunologic response to HAART. Clin Infect Dis 2003; 37(11):1541-1548

Barber SA, Bennet JM, DeWitt JB, Tarwater PM, Zink MC. Dysregulation of mitogen-activated protein kinase (MAPK) signaling pathways in SIV Encephalitis. Am J Pathol 2004; 164(2):355-62.

Chatterjee R, Tarwater P, Neogi D, Ghosh A, Roy P, and Gupta P. Estimation of HIV seroprevalence in blood bank camps in Kolkata, India. Tranfus Med 2004; 14(1):77-8.

Gibbs SG, Green CF, Tarwater PM, Scarpino PV. Airborne Antibiotic Resistant and Non-Resistant Bacteria and Fungi Recovered from Two Swine Herd Confined Animal Feeding Operations. J Occupational and Environmental Hygiene 2004; 1(11): 699-706.

Philpott S, Burger H, Tarwater PM, Lu M, Gange SJ, Anastos K, Cohen M, Greenblatt RM, Kovacs A, Minkoff H, Young M, Miotti P, Dupuis M, Chen CH, Weiser B. CCR2 geneotype and disease progression in HIV-1 infected women. Clin Infect Dis 2004; 39(6):861-5.

Tarwater PM, Gallant JE, Mellors JW, Gore ME, Phair JP, Detels R, Margolick JB, and Munoz A. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS 2004; 18:2419-2423.

Rue SM, Roos JW, Tarwater PM, Clements JE, and Barber SA. Temporal phosphorylation of simian immunodeficiency virus capsid protein. J Virol 2005; 79(4):2484-2492.

Grant LA, Tarwater PM, Schneider M, Anastos K, Cohen M., Khalsa A, Minkoff H, Young M, Greenblatt RM. Temporal Trends and Determinants of HAART Discontinuation in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr 2005; 38(4):500-503.